Elevation Oncology Inc (NASDAQ: ELEV) on Friday, plunged -6.67% from the previous trading day, before settling in for the closing price of $0.57. Within the past 52 weeks, ELEV’s price has moved between $0.36 and $5.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 41.26%. With a float of $49.99 million, this company’s outstanding shares have now reached $59.11 million.
Let’s determine the extent of company efficiency that accounts for 29 employees. In terms of profitability, gross margin is 43.1%, operating margin of -68444.83%, and the pretax margin is -68381.03%.
Elevation Oncology Inc (ELEV) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Elevation Oncology Inc is 15.43%, while institutional ownership is 84.38%.
Elevation Oncology Inc (ELEV) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.25 earnings per share (EPS) for the period topping the consensus outlook (set at -0.32) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.26% per share during the next fiscal year.
Elevation Oncology Inc (NASDAQ: ELEV) Trading Performance Indicators
Elevation Oncology Inc (ELEV) is currently performing well based on its current performance indicators. A quick ratio of 41.10 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Elevation Oncology Inc (ELEV)
Looking closely at Elevation Oncology Inc (NASDAQ: ELEV), its last 5-days average volume was 0.56 million, which is a drop from its year-to-date volume of 1.59 million. As of the previous 9 days, the stock’s Stochastic %D was 13.40%. Additionally, its Average True Range was 0.05.
During the past 100 days, Elevation Oncology Inc’s (ELEV) raw stochastic average was set at 1.18%, which indicates a significant decrease from 14.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.87% in the past 14 days, which was lower than the 172.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6067, while its 200-day Moving Average is $2.6081. However, in the short run, Elevation Oncology Inc’s stock first resistance to watch stands at $0.5664. Second resistance stands at $0.5967. The third major resistance level sits at $0.6125. If the price goes on to break the first support level at $0.5203, it is likely to go to the next support level at $0.5045. Now, if the price goes above the second support level, the third support stands at $0.4742.
Elevation Oncology Inc (NASDAQ: ELEV) Key Stats
Market capitalization of the company is 29.57 million based on 59,107K outstanding shares. Right now, sales total 0 K and income totals -45,700 K. The company made 0 K in profit during its latest quarter, and -10,460 K in sales during its previous quarter.
